← All indications
Hypertrophy
General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).
Subtype terms (3)
More specific conditions that are subtypes of Hypertrophy in the MeSH hierarchy.
- Cardiomegaly
11 drugs (9 approved, 2 experimental)
- Hepatomegaly
7 drugs (6 approved, 1 experimental)
- Splenomegaly
15 drugs (14 approved, 1 experimental)
Drugs by status
Phase 4 trials (2)
Phase 3 trials (6)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (53)
- Takeda
- Bristol-Myers Squibb
- Astellas
- Gilead Sciences
- AstraZeneca
- Merck
- Pfizer
- Sanofi
- Novartis
- Allergan
- GlaxoSmithKline
- JW Pharmaceutical
- Boehringer Ingelheim
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Dr. Sami Ulus Children's Hospital
- Guangzhou Women and Children's Medical Center
- Aarhus University
- University of Pennsylvania
- Advanced Center for Specialty Care
- Brown University
- Harvard University
- Duke University
- Guangzhou Medical University
- Instituto de Urologia e Nefrologia
- Julius-Maximilians University
- Kaohsiung Medical University
- Mahidol University
- Nagoya University
- Mustafa Kemal University
- Rhode Island Hospital
- +23 more
Organization Involved with Phase 3 Indications (54)
- Abbott
- AbbVie
- Spectrum Pharmaceuticals
- AEterna Zentaris
- Medy-Tox
- MyoKardia, Inc.
- Daewoong Pharmaceutical Co. LTD.
- Fundación Lindavista del Corazón AC
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- United States Army
- University of Manitoba
- Baylor University
- University of London
- Emory University
- Henry Ford Health System
- Indiana University
- New York University
- Newcastle University
- Northwestern University
- University of Florence
- University of Iowa
- University of Maryland
- University of Ottawa
- University of Regensburg
- University of Southern Denmark
- University of Sussex
- University of Alberta
- University of Birmingham
- University of Bordeaux
- +24 more
Organization Involved with Phase 2 Indications (33)
- American Medical Systems
- Array BioPharma
- Bayer
- Endo Pharmaceuticals
- Hugel
- Menarini Group
- Sirnaomics
- Cytokinetics
- Synvista Therapeutics, Inc
- The Foundation Institute San Raffaele G. Giglio of Cefalù
- University of Pittsburgh
- Flinders University
- Laser and Skin Surgery Center of New York
- Ohio State University
- University of Lisbon
- University of Athens
- Wroclaw Medical University
- University of Copenhagen
- Université catholique de Louvain
- Department of Defense
- Chung-Ang University
- RXi Pharmaceuticals
- Government of Russia
- University of Oxford
- European Society of Cardiology
- University of Nantes
- Vita-Salute University of Milano. Italy
- University of Goettingen
- University of Brescia
- Department of Veteran Affairs
- +3 more
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (28)
- Rottapharm
- University of Illinois
- Case Western Reserve University
- Gazi University
- McMaster University
- Melbourne Health
- Universidade Estadual de Londrina
- University of Leeds
- University of Pavia
- University of Tehran
- University of Bergen
- Wayne State University
- Yonsei University
- Taichung Veterans General Hospital
- Tel Aviv University
- University of California, San Francisco
- University of Nairobi
- University of Utah
- University of Sao Paulo
- University of Wisconsin
- Government of Kenya
- Universidade Norte do Paraná
- San Francisco State University
- California State University, Fullerton
- Legion Athletics, Inc
- Scientific Research Foundation for Fitness and Nutrition
- Marymount University
- Lindenwood University